Direct-compression blends containing a standardised dry extract of Valerianae Jatamansi Rhizoma Et Radix, adjusted to 0.8%–1.2% total valepotriates calculated as valtrate, are processed by roller compaction on a Gerteis Mini-Pactor or equivalent with roll force 4–8 kN/cm, followed by compression on a 20 kN rotary tablet press fitted with forced feeders at 15–25 rpm and lower punch pre-compression at 5–7 kN. The extract is incorporated at 6.0%–12.0% w/w of final tablet core mass, corresponding to 25–150 mg extract per tablet or 40–80 mg extract per size-3 capsule. The compliance envelope includes USP <561> for botanical identity, microscopic examination, and foreign matter; USP <467> and VICH GL18 for residual solvents with a limit of not more than 50 ppm ethanol and 10 ppm methanol depending on the extraction solvent; USP <61> and USP <62> for total aerobic microbial count, total yeast and mould count, and absence of Escherichia coli, Salmonella, and Staphylococcus aureus; and USP <232>/USP <233> for elemental impurities where an oral veterinary medicinal product is registered under EU Regulation 2019/6. Downstream production steps include pre-drying the extract at 45°C ± 2°C in a vacuum tray dryer to moisture below 3.5%, dry granulation to a granule fraction with d50 between 150 µm and 850 µm, blending in a 1,000 L bin blender for 20 min, lubrication with magnesium stearate at 1.0% w/w for 4–5 min, and film coating with a 15% w/w aqueous HPMC system at 38°C–42°C product bed temperature. Terminal finished product types include scored uncoated tablets of 25 mg, 50 mg, and 100 mg extract, HPMC film-coated tablets for odour masking, and hypromellose capsules filled with the roller-compacted granulate at 40–80 mg extract per capsule. Operational boundaries observed on production batches include granule tap density below 0.55 g/mL causing die-fill weight variation above 3.0%, overlubrication above 6 min resulting in hardness drop below 60 N, and storage at relative humidity above 60% requiring re-drying before compression because valepotriate esters absorb atmospheric moisture.

What Limits Sterile Filtration of Valepotriate-Rich Aqueous Solutions for Premedication Injectables?

The inclusion of jatamansi dry extract in injectable solutions is constrained by the hydrolytic sensitivity of valepotriate esters in aqueous media at pH above 7.2 and by ethanol-soluble lipophilic fractions that reduce downstream filter throughput through 0.22 µm PVDF capsule filters. A premedication injectable is formulated with 10–30 mg/mL of extract, equivalent to 1.0%–3.0% w/v, in water for injection adjusted to pH 6.0–7.0 with 10 mg/mL citric acid–sodium citrate buffer; sodium metabisulfite 0.05%–0.10% w/v is included as antioxidant, and polysorbate 80 is limited to 0.5% w/v because higher concentrations depress surface tension and encourage foaming during aseptic filling on 2 mL/min peristaltic lines. Regulatory and compendial controls include USP <71> for sterility by membrane filtration, USP <85> for bacterial endotoxins with an acceptance limit of ≤0.5 EU/mg of extract, USP <467>/VICH GL18 for residual extraction solvents, USP <232>/USP <233> for elemental impurities, and VICH GL11 for unspecified degradation products when the product is registered as a veterinary medicinal product. Production is performed in an isolation system under ISO 8 background with ISO 5 filling zone; the extract is first dissolved in ethanol as a 20% w/v stock, diluted under nitrogen-flushed closed stainless steel vessels at 2°C–8°C, filtered through a 0.45 µm PVDF prefilter and a 0.22 µm sterilising-grade PVDF membrane, and filled into amber USP Type I glass vials under nitrogen purge. Terminal presentations are 10 mL and 20 mL single-dose vials, 50 mL multi-dose vials preserved with 1.0% w/v benzyl alcohol, and companion diluent sachets for slow intravenous infusion. Published data for this specific parenteral configuration in target species is limited, and the maximum safe dosing rate must be established through pilot pharmacokinetic work before line scale-up.

Stress-Reduction Premixes Are Coated Post-Pelletising on Phytogenic Carrier Blends

Feed-grade premixes intended for stress-period supplementation are manufactured by post-pelletising spray coating rather than direct mixer addition because the pelleting conditioner exposes dry extract to steam at 70°C–85°C for 20–40 s, reducing total valepotriate content by 8%–15% in sealed rotary conditioner trials. The dry extract is first dispersed at 10.0% w/w in a propylene glycol–glycerol liquid carrier at 40°C ± 2°C, then metered through an air-atomising lance at 0.25–1.0 kg coating solution per tonne of cooled pelleted feed; this corresponds to 25–100 mg extract per kg complete feed and an extract addition ratio of 0.0025%–0.010% w/w of final complete feed. Compliance standards include Regulation (EC) No 183/2005 feed hygiene for premix plants, ISO 22000:2018 for food safety management, FAMI-QS for specialty feed ingredients, Regulation (EC) No 767/2009 for marketing of complementary feeds without medicinal claims, and Directive 2002/32/EC for undesirable substances in feed. Downstream production equipment includes a 1,000 kg vacuum coater with 0.2–0.4 bar internal pressure, a cooled pellet elevator maintaining product temperature 35°C–40°C, and moisture-sealed 25 kg multi-layer paper bags with an inner polyethylene liner. Finished premix formats available for commercial release include 5 kg, 10 kg, and 25 kg premix bags for feed mills, pelleted top-dress supplements at 0.5%–1.0% moisture, and mineral carrier blends for on-farm mixing. Field observation on 1,000 kg ploughshare mixers indicates that direct dry blending without coating creates segregation when the extract particle density deviates from the carrier by more than 0.30 g/mL.

Equine calming powders manufactured by jet milling require the extract to be coprocessed with a hygroscopic carrier because the native dry extract has a glass transition temperature below 40°C and becomes tacky during milling under uncontrolled humidity. The formulation uses 2.0%–5.0% w/w of jatamansi dry extract in a dextrose-maltodextrin base, with silicon dioxide at 1.0% w/w as flow aid, delivering 0.5–1.5 g extract per 500 kg equine daily dose when the finished powder is administered at 15–30 g per animal. Compliance standards for this product category include ISO 22000:2018 for feed and supplement safety, FAMI-QS for specialty feed ingredients, Regulation (EC) No 183/2005 for feed hygiene, and USP <61>/USP <62> for nonsterile microbial limits where the product is marketed as a veterinary supplement; no therapeutic claim is permitted without registration under EU Regulation 2019/6 or the relevant national veterinary medicines authority. Downstream processing is carried out in a 200 L fluid-bed jet mill with classifier speed set to yield d90 ≤75 µm, followed by V-blender mixing for 15 min at ≤30% RH, and vertical form-fill-seal packaging with nitrogen flushing to maintain headspace oxygen below 3.0%. Final commercial presentations include 500 g and 1 kg tubs with desiccant closures, 30 g single-dose sachets, and apple-flavoured oral paste syringes using a 10% w/w extract dispersion in a palatability base.

When Molasses-Based Licks Replace Daily Top-Dress Powders in Slow-Release Stress Palatability Systems

In bucket-lick manufacturing, the incorporation of jatamansi extract into molasses-based matrices is limited by Maillard reactivity between reducing sugars and extract constituents above 75°C; production therefore uses steam-jacketed ploughshare mixers with jacket temperature 65°C ± 3°C and total hot-mix residence time not exceeding 10 min. The extract is added at 0.2%–0.5% w/w of the finished lick mass, corresponding to 2–5 g extract per 1 kg block, because higher inclusion rates cause rejection scores above 3.0 on a five-point equine/bovine palatability acceptance test. Compliance standards include Regulation (EC) No 183/2005 for feed hygiene, Regulation (EC) No 767/2009 for labelling of complementary feed materials, FAMI-QS for traceability, and Directive 2002/32/EC for heavy metal and dioxin limits. Downstream production involves pre-blending the extract with calcium carbonate at 1:5 ratio to prevent clumping, metering into a 500 kg ploughshare mixer with 20 rpm chopper speed, filling into 20 kg polypropylene buckets, and curing at 20°C–25°C for 24 h to reach final hardness 2.0–3.5 kg/cm². End-product formats are 20 kg bucket licks, 1 kg pressed blocks, and 500 g granular molasses-encapsulated supplements for addition to feed.

Drinking-Water Soluble Powder Constraints Under Hard-Water Alkalinity

Hard-water alkalinity above 180 mg/L CaCO₃ reduces the apparent solubility of native jatamansi extract powders by precipitating acidic valepotriate hydrolysis products and raising the pH of the reconstituted solution above 7.8, which accelerates degradation. A drinking-water soluble formulation is prepared by co-spray-drying the extract onto maltodextrin at 20%–30% w/w, adding citric acid at 5.0%–8.0% w/w to the final powder to buffer the stock solution to pH 4.5–5.5, and including sodium bicarbonate at 3.0%–4.0% w/w as an effervescent carrier where rapid dissolution is required. The extract addition ratio is 0.1–0.5 g/L of drinking water, equivalent to 0.01%–0.05% w/v, depending on target species and duration of administration. Compliance standards include USP <61>/USP <62> for microbiological quality, USP <467> for residual solvents, ISO 22000:2018 for process hygiene, and national drinking-water medication guidelines for veterinary oral solutions; if the product is used in food-producing animals, withdrawal periods must be justified under the relevant residue control framework. Downstream production uses a 50 L spray dryer with inlet temperature 140°C–160°C and outlet temperature 65°C–75°C, followed by vacuum blending at ≤25% RH and filling into 100 g, 500 g, and 1 kg foil-lined sachets. Terminal finished product types include water-soluble powders for proportioner medicators, effervescent tablets of 2 g extract per tablet, and liquid concentrate bottles with 10% w/v extract for stock solution preparation.